Janus Henderson Group PLC Purchases 501,752 Shares of Liquidia Co. (NASDAQ:LQDA)

Janus Henderson Group PLC boosted its position in Liquidia Co. (NASDAQ:LQDA) by 1,484.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 535,552 shares of the company’s stock after acquiring an additional 501,752 shares during the period. Janus Henderson Group PLC’s holdings in Liquidia were worth $6,293,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LQDA. Steward Partners Investment Advisory LLC bought a new position in Liquidia in the fourth quarter worth approximately $59,000. Summit Investment Advisors Inc. lifted its holdings in shares of Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock valued at $78,000 after purchasing an additional 1,719 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new position in shares of Liquidia in the fourth quarter valued at approximately $142,000. EntryPoint Capital LLC bought a new position in shares of Liquidia in the fourth quarter valued at approximately $154,000. Finally, Bayesian Capital Management LP bought a new position in shares of Liquidia in the fourth quarter valued at approximately $163,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Trading Down 2.2%

Shares of Liquidia stock opened at $18.88 on Friday. The business’s fifty day simple moving average is $14.56 and its 200 day simple moving average is $13.40. The firm has a market capitalization of $1.61 billion, a P/E ratio of -11.58 and a beta of 0.24. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $19.41.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). The business had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. Analysts predict that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other Liquidia news, General Counsel Russell Schundler sold 5,964 shares of the firm’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $80,931.48. Following the completion of the sale, the general counsel now directly owns 570,301 shares of the company’s stock, valued at $7,738,984.57. This trade represents a 1.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Rajeev Saggar sold 2,450 shares of the firm’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the completion of the sale, the insider now directly owns 263,152 shares of the company’s stock, valued at $3,597,287.84. This represents a 0.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock valued at $450,233 over the last ninety days. 30.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Raymond James raised their target price on Liquidia from $27.00 to $29.00 and gave the company a “strong-buy” rating in a report on Friday, May 9th. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a report on Monday, May 12th. Needham & Company LLC restated a “buy” rating and issued a $25.00 target price on shares of Liquidia in a report on Monday, May 12th. Finally, Scotiabank restated an “outperform” rating on shares of Liquidia in a report on Monday, May 5th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $27.13.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).